Rising Schizophrenia in Female Population is Offering Steady Growth to Indian Schizophrenia Drugs Market

Published: Sep 2020

Indian schizophrenia drugs market is projected to grow at a significant CAGR of 4.0% during the forecast period (2020-2026). The major contributors in the market are the female population suffering from mental health issues in the country. There is no gender difference in schizophrenia; however, a stress and mental health are some factors leads to schizophrenia. In India, women face a lot of problems in India, especially in relation to pregnancy, marriage, childbirth, and menopause. There is no clear trend has been stated till date of schizophrenia with mortality, although suicides seem to be more in women with schizophrenia in India. 

Browse the full report description of "Indian Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Therapeutic Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, and Others) and by Treatment (Oral and Injectables) and Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/indian-schizophrenia-drugs-market

Moreover, the rising healthcare spending and awareness for metal health in the country is leading to the schizophrenia drugs market growth in India. A number of mental healthcare institutions have established in the period of past 5 years. Therefore, a significant market is expected in India during the forecast period. Women are expected to contribute significantly in the market in India. The Government of India is taking several steps to monitor and control the mental disorders in the country. Moreover, the government regularly conducts surveys for mental health in India, which in turn, assist in the growth of the schizophrenia drug market in the country.

Market Coverage

Report Elements

Details

Study Period

2019-2026

Base year

2019

Forecast period

2020-2026

Segments Covered

By Therapeutic Class and By Treatment

Key Companies Profiled

Allergan PLC, Catalent, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc.


Key questions addressed by the report

  • What is the market growth rate during the forecast period?
  • Which segment/region dominates the market in the base year?
  • Which segment/region will project the fastest growth in the market during the forecast period?
  • How COVID-19 will impact the market growth in 2020 and coming years?

o Recovery Timeline

o Deviation from pre-COVID-19

o Most affected region/segment

o Recommendations 

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Indian Schizophrenia Drugs Market – Segmentation

By Therapeutic Class

  • Second Generation Antipsychotics 
  • Third Generation Antipsychotics
  • Others (First Generation Antipsychotics)

By Treatment

  • Oral 
  • Injectables

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/indian-schizophrenia-drugs-market